Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pfizer Inc. stock logo
PFE
Pfizer
$25.38
+0.5%
$26.96
$25.20
$40.37
$143.72B0.6142.01 million shs46.48 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pfizer Inc. stock logo
PFE
Pfizer
+0.48%-2.35%-8.61%-7.61%-34.30%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Pfizer Inc. stock logo
PFE
Pfizer
4.9751 of 5 stars
3.23.04.24.83.11.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3343.16% Upside

Current Analyst Ratings

Latest PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/22/2024
Pfizer Inc. stock logo
PFE
Pfizer
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
2/23/2024
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$36.00
1/31/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
(Data available from 4/27/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.46$2.87 per share8.83$15.81 per share1.61

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3670.509.161.183.62%10.88%4.91%5/1/2024 (Confirmed)

Latest PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.62%+2.57%466.67%15 Years

Latest PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

PFE Headlines

SourceHeadline
Pfizer’s First Gene Therapy Gets Approval for Clotting DisorderPfizer’s First Gene Therapy Gets Approval for Clotting Disorder
bloomberg.com - April 26 at 10:34 PM
Pfizer (NYSE:PFE) Notches Up on New FDA ApprovalPfizer (NYSE:PFE) Notches Up on New FDA Approval
msn.com - April 26 at 10:34 PM
Stanley Laman Group Ltd. Buys 44,722 Shares of Pfizer Inc. (NYSE:PFE)Stanley Laman Group Ltd. Buys 44,722 Shares of Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 26 at 9:14 PM
Pfizer (NYSE:PFE) Stock Price Up 0.3%Pfizer (NYSE:PFE) Stock Price Up 0.3%
marketbeat.com - April 26 at 5:58 PM
What Factors Will Drive Pfizers Q1 Performance?What Factors Will Drive Pfizer's Q1 Performance?
forbes.com - April 26 at 5:34 PM
Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, UniqurePfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure
finance.yahoo.com - April 26 at 5:34 PM
FDA Green Lights Pfizers Gene Therapy For Rare Bleeding Disorder HemophiliaFDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
finance.yahoo.com - April 26 at 5:34 PM
Pfizer (NYSE:PFE) Sets New 52-Week Low at $25.20Pfizer (NYSE:PFE) Sets New 52-Week Low at $25.20
marketbeat.com - April 26 at 2:35 PM
GSK sues Pfizer and BioNTech over mRNA billionsGSK sues Pfizer and BioNTech over mRNA billions
thepharmaletter.com - April 26 at 12:33 PM
Pfizer Gains as Gene Therapy Wins FDA NodPfizer Gains as Gene Therapy Wins FDA Nod
baystreet.ca - April 26 at 12:33 PM
FDA approves Pfizer’s gene therapy Beqvez for adults with hemophilia BFDA approves Pfizer’s gene therapy Beqvez for adults with hemophilia B
thepharmaletter.com - April 26 at 12:33 PM
Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key MetricsGear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics
zacks.com - April 26 at 10:21 AM
Pfizer Receives FDA Approval for Bleeding Disorder TreatmentPfizer Receives FDA Approval for Bleeding Disorder Treatment
barrons.com - April 26 at 9:35 AM
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 StocksWant $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
fool.com - April 26 at 7:45 AM
Pfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia BPfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia B
marketwatch.com - April 26 at 7:33 AM
Pfizers Beqvez Receives FDA Approval For Treatment Of Adults With Hemophilia BPfizer's Beqvez Receives FDA Approval For Treatment Of Adults With Hemophilia B
markets.businessinsider.com - April 26 at 7:33 AM
US FDA approves Pfizers gene therapy for rare bleeding disorderUS FDA approves Pfizer's gene therapy for rare bleeding disorder
reuters.com - April 26 at 7:33 AM
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia BU.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
finance.yahoo.com - April 26 at 7:33 AM
Pfizer Now Rivals The Worlds Most Expensive Medicine After FDA Approves Gene TherapyPfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
finance.yahoo.com - April 26 at 7:33 AM
UPDATE 2-US FDA approves Pfizers gene therapy for rare bleeding disorderUPDATE 2-US FDA approves Pfizer's gene therapy for rare bleeding disorder
finance.yahoo.com - April 26 at 7:33 AM
FDA approves Pfizers first gene therapy for rare inherited bleeding disorderFDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
cnbc.com - April 26 at 7:02 AM
U.S. FDA Approves Pfizers BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia BU.S. FDA Approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
businesswire.com - April 26 at 6:45 AM
Pfizer (NYSE:PFE) Trading Down 2.5%Pfizer (NYSE:PFE) Trading Down 2.5%
marketbeat.com - April 25 at 6:18 PM
Syon Capital LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)Syon Capital LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 25 at 5:33 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.